Yervoy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Yervoy market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising incidence of cancer, a growing focus on combination therapies, regulatory approvals for new indications, advancements in biologic manufacturing, and increased investments in oncology research.

Market growth during the forecast period is expected to be driven by rising consumer demand in emerging markets, expanding applications across industries, advancements in clinical research, increasing investment in biologics, and global market expansion. Key trends include the expansion of combination immunotherapies, the broadening of indications for new cancers, advancements in biologic drug delivery systems, the increasing role of artificial intelligence (AI) in oncology, and a focus on patient-centric drug development.

The growing incidence of melanoma is expected to drive the expansion of the yervoy market. Melanoma is a form of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. The rise in melanoma cases can be attributed to factors like increased sun exposure, lifestyle changes, and higher UV radiation levels due to ozone depletion. Additionally, better awareness and diagnostic techniques have led to more cases being identified. Yervoy, which targets the CTLA-4 protein to enhance the immune system’s ability to recognize and destroy cancer cells, has shown significant benefits for melanoma patients, improving survival rates and providing long-lasting responses even in the later stages of the disease. According to the American Cancer Society, about 100,640 new melanoma cases are expected in the United States in 2024, with 59,170 in men and 41,470 in women. The society also estimates that 8,290 people will die from melanoma in 2024, with 5,430 men and 2,860 women affected. As a result, the rising number of melanoma cases is driving growth in the yervoy market.

A key trend in the yervoy market is the development of innovative combination therapies, such as pairing Opdivo (nivolumab) with Yervoy (ipilimumab) to improve treatment outcomes and extend their application to more cancer types. This combination works synergistically to enhance the immune response by targeting different immune checkpoint pathways, which improves effectiveness in treating cancers like melanoma and renal cell carcinoma. For example, in June 2024, Bristol Myers Squibb, a US-based pharmaceutical company, announced promising results from the CheckMate-9DW trial. The trial tested the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The results showed that this dual immunotherapy significantly improved overall survival compared to the standard treatments, lenvatinib or sorafenib. The combination demonstrated a statistically significant survival benefit for advanced HCC patients compared to those treated with either lenvatinib or sorafenib.

In September 2024, Ono Pharmaceutical, a Japanese pharmaceutical company, formed a partnership with Bristol-Myers Squibb KK (BMS KK) to expand the use of Opdivo and Yervoy for treating unresectable advanced or recurrent microsatellite instability-high (MSI-H) colorectal cancer. This collaboration aims to strengthen Ono’s portfolio of immuno-oncology therapies and address the unmet medical needs in cancer treatment. Bristol-Myers Squibb is the company behind Yervoy.

Major players operating in the yervoy market are Bristol-Myers Squibb, Merck & Co., and Ono Pharmaceutical.

North America was the largest region in the yervoy market in 2024. The regions covered in yervoy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the yervoy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Yervoy is a prescription medication containing ipilimumab, a monoclonal antibody used to treat certain cancers by enhancing the body's immune system to fight cancer cells. It works by blocking the CTLA-4 (cytotoxic T-lymphocyte antigen 4) receptor on T-cells, which normally downregulates the immune response.

The main types of yervoy are the 40 ml and 10 ml doses. The Yervoy 40 mg dose refers to a specific concentration of ipilimumab, used in immunotherapy to activate the immune system by inhibiting CTLA-4. This enhances the body's ability to target and destroy cancer cells, especially in conditions like metastatic melanoma and other cancers as per the prescribed treatment regimen. Yervoy is indicated for melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal cancer (CRC). It is distributed through various channels such as hospitals, oncology clinics, retail pharmacies, and online pharmacies, and is used by various end users including adults and the geriatric population.

The yervoy market research report is one of a series of new reports that provides yervoy market statistics, including yervoy industry global market size, regional shares, competitors with a yervoy market share, detailed yervoy market segments, market trends, and opportunities, and any further data you may need to thrive in the yervoy industry. This yervoy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The yervoy market consists of sales of ipilimumab and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.